[1]
|
Savarese, G., Becher, P.M., Lund, L.H., et al. (2023) Global Burden of Heart Failure: A Comprehensive and Updated Review of Epidemiology. Cardiovascular Research, 118, 3272-3287. https://doi.org/10.1093/cvr/cvac013
|
[2]
|
Heidenreich, P.A., Bozkurt, B., Aguilar, D., et al. (2022) ACC/AHA/HFSA Guideline for the Management of Heart Failure. Journal of Cardiac Failure, 28, e1-e167. https://doi.org/10.1016/j.cardfail.2022.02.009
|
[3]
|
Gladden, J.D., Chaanine, A.H. and Redfield, M.M. (2018) Heart Failure with Preserved Ejection Fraction. Annual Review of Medicine, 69, 65-79. https://doi.org/10.1146/annurev-med-041316-090654
|
[4]
|
Omote, K., Verbrugge, F.H. and Borlaug, B.A. (2022) Heart Failure with Preserved Ejection Fraction: Mechanisms and Treatment Strategies. Annual Review of Medicine, 73, 321-337. https://doi.org/10.1146/annurev-med-042220-022745
|
[5]
|
Tsao, C.W., Lyass, A., Enserro, D., et al. (2018) Temporal Trends in the Incidence of and Mortality Associated with Heart Failure with Preserved and Reduced Ejection Fraction. JACC: Heart Fail, 6, 678-685. https://doi.org/10.1016/j.jchf.2018.03.006
|
[6]
|
Heidenreich, P.A., Bozkurt, B., Aguilar, D., et al. (2022) AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 145, e895-e1032. https://doi.org/10.1161/CIR.0000000000001073
|
[7]
|
Anker, S.D., Butler, J., Filippatos, G., et al. (2021) Empagliflozin in Heart Failure with a Preserved Ejection Fraction. The New England Journal of Medicine, 385, 1451-1461. https://doi.org/10.1056/NEJMoa2107038
|
[8]
|
Solomon, S.D., McMurray, J.J.V., Claggett, B., et al. (2022) Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. The New England Journal of Medicine, 387, 1089-1098. https://doi.org/10.1056/NEJMoa2206286
|
[9]
|
Bhatt, D.L., Szarek, M., Steg, P.G., et al. (2021) Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. The New England Journal of Medicine, 384, 117-128. https://doi.org/10.1056/NEJMoa2030183
|
[10]
|
Cowart, K. and Carris, N.W. (2021) Evaluation of Cardiovascular and Renal Outcomes with Ertugliflozin: What Is the VERdict from the VERTIS-CV Trial? Expert Opinion on Pharmacotherapy, 22, 163-165. https://doi.org/10.1080/14656566.2020.1822327
|
[11]
|
Zhazykbayeva, S., Pabel, S., Mügge, A., et al. (2020) The Molecular Mechanisms Associated with the Physiological Responses to Inflammation and Oxidative Stress in Cardiovascular Diseases. Biophysical Reviews, 12, 947-968. https://doi.org/10.1007/s12551-020-00742-0
|
[12]
|
Kolijn, D., Pabel, S., Tian, Y., et al. (2021) Empagliflozin Improves Endothelial and Cardiomyocyte Function in Human Heart Failure with Preserved Ejection Fraction via Reduced Pro-Inflammatory-Oxidative Pathways and Protein Kinase Galpha Oxidation. Cardiovascular Research, 117, 495-507. https://doi.org/10.1093/cvr/cvaa123
|
[13]
|
Cappetta, D., De Angelis, A., Ciuffreda, L.P., et al. (2020) Amelioration of Diastolic Dysfunction by Dapagliflozin in a Non-Diabetic Model Involves Coronary Endothelium. Pharmacological Research, 157. Article 104781. https://doi.org/10.1016/j.phrs.2020.104781
|
[14]
|
Scisciola, L., Cataldo, V., Taktaz, F., et al. (2022) Anti-Inflammatory Role of SGLT2 Inhibitors as Part of Their Anti-Atherosclerotic Activity: Data from Basic Science and Clinical Trials. Frontiers in Cardiovascular Medicine, 9, Article 1008922. https://doi.org/10.3389/fcvm.2022.1008922
|
[15]
|
Venteclef, N., Guglielmi, V., Balse, E., et al. (2015) Human Epicardial Adipose Tissue Induces Fibrosis of the Atrial Myocardium through the Secretion of Adipo-Fibrokines. European Heart Journal, 36, 795-805. https://doi.org/10.1093/eurheartj/eht099
|
[16]
|
Iacobellis, G. (2022) Epicardial Adipose Tissue in Contemporary Cardiology. Nature Reviews Cardiology, 19, 593-606. https://doi.org/10.1038/s41569-022-00679-9
|
[17]
|
Mullens, W., Martens, P. (2021) Empagliflozin-Induced Changes in Epicardial Fat: The Centerpiece for Myocardial Protection? JACC: Heart Fail, 9, 590-593. https://doi.org/10.1016/j.jchf.2021.05.006
|
[18]
|
Salvatore, T., Galiero, R., Caturano, A., et al. (2022) An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors. International Journal of Molecular Sciences, 23, 3651-3695. https://doi.org/10.3390/ijms23073651
|
[19]
|
Yagi, S., Hirata, Y., Ise, T., et al. (2017) Canagliflozin Reduces Epicardial Fat in Patients with Type 2 Diabetes Mellitus. Diabetology & Metabolic Syndrome, 9, Article 78. https://doi.org/10.1186/s13098-017-0275-4
|
[20]
|
Bouchi, R., Terashima, M., Sasahara, Y., et al. (2017) Luseogliflozin Reduces Epicardial Fat Accumulation in Patients with Type 2 Diabetes: A Pilot Study. Cardiovascular Diabetology, 16, Article No. 32. https://doi.org/10.1186/s12933-017-0516-8
|
[21]
|
Fukuda, T., Bouchi, R., Terashima, M., et al. (2017) Ipragliflozin Reduces Epicardial Fat Accumulation in Non-Obese Type 2 Diabetic Patients with Visceral Obesity: A Pilot Study. Diabetes Therapy, 8, 851-861. https://doi.org/10.1007/s13300-017-0279-y
|
[22]
|
Masson, W., Lavalle-Cobo, A. and Nogueira, J.P. (2021) Effect of SGLT2-Inhibitors on Epicardial Adipose Tissue: A Meta-Analysis. Cells, 10, Article 2150. https://doi.org/10.3390/cells10082150
|
[23]
|
De Lorenzi, A.B., Kaplinsky, E., Zambrano, M.R., et al. (2023) Emerging Concepts in Heart Failure Treatment and Management: Focus on SGLT2 Inhibitors in Heart Failure with Preserved Ejection Fraction. Drugs in Context, 12, 1-16. https://doi.org/10.7573/dic.2022-7-1
|
[24]
|
Zuurbier, C.J., Baartscheer, A., Schumacher, C.A., et al. (2021) Sodium-Glucose Co-Transporter 2 Inhibitor Empagliflozin Inhibits the Cardiac Na /H Exchanger 1: Persistent Inhibition under Various Experimental Conditions. Cardiovascular Research, 117, 2699-2701. https://doi.org/10.1093/cvr/cvab129
|
[25]
|
Trum, M., Riechel, J., Lebek, S., Pabel, S., et al. (2020) Empagliflozin Inhibits Na /H Exchanger Activity in Human Atrial Cardiomyocytes. ESC Heart Failure, 7, 4429-4437. https://doi.org/10.1002/ehf2.13024
|
[26]
|
Meagher, P., Adam, M. and Connelly, K. (2020) It’s Not All about the Cardiomyocyte: Fibroblasts, Empagliflozin, and Cardiac Remodelling. Canadian Journal of Cardiology, 36, 464-466. https://doi.org/10.1016/j.cjca.2019.10.017
|
[27]
|
Kang, S., Verma, S., Hassanabad, A.F., et al. (2020) Direct Effects of Empagliflozin on Extracellular Matrix Remodelling in Human Cardiac Myofibroblasts: Novel Translational Clues to Explain EMPA-REG OUTCOME Results. Canadian Journal of Cardiology, 36, 543-553. https://doi.org/10.1016/j.cjca.2019.08.033
|
[28]
|
Fang, J.C. (2016) Heart Failure with Preserved Ejection Fraction: A Kidney Disorder? Circulation, 134, 435-437. https://doi.org/10.1161/CIRCULATIONAHA.116.022249
|
[29]
|
Gori, M., Senni, M., Gupta, D.K., et al. (2014) Association between Renal Function and Cardiovascular Structure and Function in Heart Failure with Preserved Ejection Fraction. European Heart Journal, 35, 3442-3451. https://doi.org/10.1093/eurheartj/ehu254
|
[30]
|
Wanner, C., Heerspink, H.J.L., Zinman, B., et al. (2018) Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial. Journal of the American Society of Nephrology, 29, 2755-2769. https://doi.org/10.1681/ASN.2018010103
|
[31]
|
Hallow, K.M., Helmlinger, G., Greasley, P.J., et al. (2018) Why Do SGLT2 Inhibitors Reduce Heart Failure Hospitalization? A Differential Volume Regulation Hypothesis. Diabetes, Obesity and Metabolism, 20, 479-487. https://doi.org/10.1111/dom.13126
|
[32]
|
Karagodin, I., Aba-Omer, O., Sparapani, R., et al. (2017) Aortic Stiffening Precedes Onset of Heart Failure with Preserved Ejection Fraction in Patients with Asymptomatic Diastolic Dysfunction. BMC Cardiovascular Disorders, 17, Article No. 62. https://doi.org/10.1186/s12872-017-0490-9
|
[33]
|
Saucedo-Orozco, H., Voorrips, S.N., Yurista, S.R., et al. (2022) SGLT2 Inhibitors and Ketone Metabolism in Heart Failure. Journal of Lipid and Atherosclerosis, 11, 1-19. https://doi.org/10.12997/jla.2022.11.1.1
|
[34]
|
Kappel, B.A., Lehrke, M., Schütt, K., et al. (2017) Effect of Empagliflozin on the Metabolic Signature of Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease. Circulation, 136, 969-972. https://doi.org/10.1161/CIRCULATIONAHA.117.029166
|
[35]
|
Zelniker, T.A. and Braunwald, E. (2020) Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review. Journal of the American College of Cardiology, 75, 422-434. https://doi.org/10.1016/j.jacc.2019.11.031
|
[36]
|
Packer, M. (2020) Autophagy Stimulation and Intracellular Sodium Reduction as Mediators of the Cardioprotective Effect of Sodium-Glucose Cotransporter 2 Inhibitors. European Journal of Heart Failure, 22, 618-628. https://doi.org/10.1002/ejhf.1732
|
[37]
|
Luo, G., Jian, Z., Zhu, Y., et al. (2019) Sirt1 Promotes Autophagy and Inhibits Apoptosis to Protect Cardiomyocytes from Hypoxic Stress. International Journal of Molecular Medicine, 43, 2033-2043. https://doi.org/10.3892/ijmm.2019.4125
|
[38]
|
Jaiswal, A., Jaiswal, V., Ang, S.P., et al. (2023) SGLT2 Inhibitors among Patients with Heart Failure with Preserved Ejection Fraction: A Meta-Analysis of Randomised Controlled Trials. Medicine (Baltimore), 102, e34693. https://doi.org/10.1097/MD.0000000000034693
|
[39]
|
周京敏, 王华, 黎励文. 射血分数保留的心力衰竭诊断与治疗中国专家共识2023 [J]. 中国循环杂志, 2023, 38(4): 375-393.
|